SUCCESSFUL TREATMENT OF A MALIGNANT RAT GLIOMA WITH CYTOTOXIC LYMPHOCYTE-T

被引:47
作者
HOLLADAY, FP [1 ]
HEITZ, T [1 ]
CHEN, YL [1 ]
CHIGA, M [1 ]
WOOD, GW [1 ]
OLSON, JJ [1 ]
机构
[1] UNIV KANSAS, MED CTR, DIV NEUROSURG, DEPT PATHOL & ONCOL, KANSAS CITY, KS 66103 USA
关键词
ASTROCYTOMA; CYTOTOXIC LYMPHOCYTES-T; GLIOMA; IMMUNOTHERAPY; TUMOR IMMUNITY;
D O I
10.1227/00006123-199209000-00015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BRAIN TUMORS ARE highly resistant to therapy. Their diffuse infiltrative nature and the relative inaccessibility of brain tissue to blood and lymph are barriers to surgical and cytotoxic treatments alike. The purpose of this study was to produce immune cells specifically reactive with an anaplastic rat glioma (RT2) and determine whether those cells could affect tumor progression in the brain. RT2-specific cytotoxic cells were prepared by priming rats in vivo with RT2 tumor cells and Corynebacterium parvum and stimulating the primed lymphocytes in vitro with irradiated RT2 tumor cells and interleukin-2 (IL-2). Cultured cells exhibited a high level of cytotoxicity against RT2, but not C6 (an allogeneic glioma), 3M2N (a syngeneic mammary tumor), or CSE (a syngeneic fibrosarcoma) tumor cells. To generate a model for therapy, rats were injected intracerebrally with RT2, generating progressing brain tumors, which killed untreated rats in approximately 2 weeks. To test the therapeutic potential of the effector cells, tumor-bearing rats were treated by intravenous injection of lymphocytes on Day 5 of tumor growth. Treated rats also received a 5-day course of systemic IL-2 beginning on Day 5. Treatment with IL-2 alone, RT2-primed spleen cells, or RT2-primed spleen cells stimulated in vitro with C6 did not affect rat survival. However, tumor-bearing rats treated with RT2-stimulated lymphocytes exhibited increased survival or were cured. Systemic IL-2 was an essential adjunct, because survival was not affected by treatment with effector cells alone. Therapy initiated on Day 8 of tumor progression lacked effect on survival. Those results demonstrated that rapidly progressing malignant brain tumors may be treated effectively by systemic administration of tumor-specific immune cells and IL-2.
引用
收藏
页码:528 / 533
页数:6
相关论文
共 48 条
[1]   IMMUNOLOGICAL ASPECTS OF INTRINSIC GLIAL TUMORS [J].
APUZZO, MLJ ;
MITCHELL, MS .
JOURNAL OF NEUROSURGERY, 1981, 55 (01) :1-18
[2]   INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].
BARBA, D ;
SARIS, SC ;
HOLDER, C ;
ROSENBERG, SA ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182
[3]  
BECKMAN WC, 1987, CANCER-AM CANCER SOC, V59, P266, DOI 10.1002/1097-0142(19870115)59:2<266::AID-CNCR2820590215>3.0.CO
[4]  
2-6
[5]  
BELLDEGRUN A, 1988, CANCER RES, V48, P206
[6]   LINKED RECOGNITION OF HELPER AND CYTO-TOXIC ANTIGENIC DETERMINANTS FOR THE GENERATION OF CYTO-TOXIC LYMPHOCYTES-T [J].
CASSELL, D ;
FORMAN, J .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 532 :51-60
[7]  
CHEEVER MA, 1981, J IMMUNOL, V126, P1318
[8]   DEFINITION OF THE ROLE OF CONTEMPORARY SURGICAL-MANAGEMENT IN CISTERNAL AND PARENCHYMATOUS CYSTICERCOSIS CEREBRI [J].
COULDWELL, WT ;
ZEE, CS ;
APUZZO, MLJ .
NEUROSURGERY, 1991, 28 (02) :231-237
[9]   IMMUNOLOGY OF GLIOMAS [J].
DETRIBOLET, N .
CHILDS NERVOUS SYSTEM, 1989, 5 (02) :60-65
[10]   PHASE-II TRIAL OF INTERFERON-BETA FOR TREATMENT OF RECURRENT GLIOBLASTOMA-MULTIFORME [J].
DUFF, TA ;
BORDEN, E ;
BAY, J ;
PIEPMEIER, J ;
SIELAFF, K .
JOURNAL OF NEUROSURGERY, 1986, 64 (03) :408-413